Use of a nanoparticle to deliver drugs may reduce tumors and suppress metastatic escape. These efforts offer a way to control drug release over space and time while reducing systemic drug exposure and the associated side effects.
I am hearing there is a new granulocyte colony-stimulating factor (G-CSF) coming out on the market. What can you tell us about this product?
Deep within most tumors lie areas that remain untouched by chemotherapy and radiation. These areas lack the blood and oxygen needed for traditional therapies to work, but provide the perfect target for a new cancer treatment.
HER2-positive breast cancer typically develops resistance to Herceptin within several years. researchers have found a means of inhibiting another protein whose expression is also upregulated in HER2-positive breast cancer.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|